A physiologically based pharmacokinetic model of ketoconazole and its metabolites as drug-drug interaction perpetrators
The antifungal ketoconazole, which is mainly used for dermal infections and treatment of Cushing’s syndrome, is prone to drug-food interactions (DFIs) and is well known for its strong drug-drug interaction (DDI) potential. Some of ketoconazole’s potent inhibitory activity can be attributed to its me...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
17 February 2023
|
| In: |
Pharmaceutics
Year: 2023, Jahrgang: 15, Heft: 2, Pages: 1-22 |
| ISSN: | 1999-4923 |
| DOI: | 10.3390/pharmaceutics15020679 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/pharmaceutics15020679 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/1999-4923/15/2/679 
|
| Verfasserangaben: | Fatima Zahra Marok, Jan-Georg Wojtyniak, Laura Maria Fuhr, Dominik Selzer, Matthias Schwab, Johanna Weiss, Walter Emil Haefel and Thorsten Lehr |
| Zusammenfassung: | The antifungal ketoconazole, which is mainly used for dermal infections and treatment of Cushing’s syndrome, is prone to drug-food interactions (DFIs) and is well known for its strong drug-drug interaction (DDI) potential. Some of ketoconazole’s potent inhibitory activity can be attributed to its metabolites that predominantly accumulate in the liver. This work aimed to develop a whole-body physiologically based pharmacokinetic (PBPK) model of ketoconazole and its metabolites for fasted and fed states and to investigate the impact of ketoconazole’s metabolites on its DDI potential. ... |
|---|---|
| Beschreibung: | Gesehen am 05.12.2023 |
| Beschreibung: | Online Resource |
| ISSN: | 1999-4923 |
| DOI: | 10.3390/pharmaceutics15020679 |